V. Lecomte

No ORCID on file · 3 papers in corpus
article 2020
Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial
Fertility and sterility ·doi:10.1016/j.fertnstert.2020.02.114

ObjectiveTo study the effect of a new investigational oral gonadotropin-releasing hormone antagonist, linzagolix, on endometriosis-associated pain (EAP).DesignA multinational, parallel group, randomized, placebo-controlled, double-blind, do…

article 2019
Long term treatment of endometriosis associated pain (EAP) with linzagolix: efficacy and safety after 12 months of treatment
·doi:10.1016/j.fertnstert.2019.07.935
article 2019
The Effect of Linzagolix on Bone Mineral Density (BMD): Safety Results From a Dose-Ranging Trial [21J]
·doi:10.1097/01.aog.0000558837.48634.b6

INTRODUCTION: Linzagolix is a new, non-peptide, GnRH receptor antagonist being developed to treat endometriosis-associated pain (EAP). The EDELWEISS trial is a Phase 2b, double-blind, randomized, placebo-controlled, multicenter, dose-rangin…